患者对基于胰岛素的减肥药物的看法及其与人口统计学因素的关系。

IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM
Obesity Science & Practice Pub Date : 2024-08-06 eCollection Date: 2024-08-01 DOI:10.1002/osp4.783
Megan A McVay, Wendy S Moore, Francesca L Wilkins, Jalen R Jackson, Michael D Robinson
{"title":"患者对基于胰岛素的减肥药物的看法及其与人口统计学因素的关系。","authors":"Megan A McVay, Wendy S Moore, Francesca L Wilkins, Jalen R Jackson, Michael D Robinson","doi":"10.1002/osp4.783","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Treatment of obesity has been transformed by the recent approval of incretin-based therapies for weight loss (e.g., glucagon-like peptide 1 agonist semaglutide), but little is known about patient perspectives on these medications.</p><p><strong>Methods: </strong>Between December 2023 and March 2024, healthcare patients from an academic medical center in the Southeast United States with Body Mass Index ≥30 kg/m<sup>2</sup> completed a cross-sectional online survey on attitudes toward incretin-based medications.</p><p><strong>Results: </strong>Compared to patients with a bachelor's degree, those without a degree were less likely to be aware of incretin-based pharmacotherapies (96% vs. 78%) and to have discussed pharmacotherapies with a doctor (43% vs. 27%) but had greater interest in using these pharmacotherapies (4.3 vs. 4.7). These pharmacotherapy-related variables did not differ significantly according to gender, race, or financial security. Concerns about side effects, long-term health risks, and potential for weight regain were highly endorsed and were associated with lower interest in using incretin-based therapies and with some demographic factors. Patients reported high interest in lifestyle programs designed for individuals taking anti-obesity medications.</p><p><strong>Conclusion: </strong>Demographic considerations, notably education level, should be factored into the strategy to promote equitable utilization of incretin-based therapies, particularly as their accessibility expands.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"10 4","pages":"e783"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302371/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patient perspectives on incretin-based weight loss medications and relationship with demographic factors.\",\"authors\":\"Megan A McVay, Wendy S Moore, Francesca L Wilkins, Jalen R Jackson, Michael D Robinson\",\"doi\":\"10.1002/osp4.783\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Treatment of obesity has been transformed by the recent approval of incretin-based therapies for weight loss (e.g., glucagon-like peptide 1 agonist semaglutide), but little is known about patient perspectives on these medications.</p><p><strong>Methods: </strong>Between December 2023 and March 2024, healthcare patients from an academic medical center in the Southeast United States with Body Mass Index ≥30 kg/m<sup>2</sup> completed a cross-sectional online survey on attitudes toward incretin-based medications.</p><p><strong>Results: </strong>Compared to patients with a bachelor's degree, those without a degree were less likely to be aware of incretin-based pharmacotherapies (96% vs. 78%) and to have discussed pharmacotherapies with a doctor (43% vs. 27%) but had greater interest in using these pharmacotherapies (4.3 vs. 4.7). These pharmacotherapy-related variables did not differ significantly according to gender, race, or financial security. Concerns about side effects, long-term health risks, and potential for weight regain were highly endorsed and were associated with lower interest in using incretin-based therapies and with some demographic factors. Patients reported high interest in lifestyle programs designed for individuals taking anti-obesity medications.</p><p><strong>Conclusion: </strong>Demographic considerations, notably education level, should be factored into the strategy to promote equitable utilization of incretin-based therapies, particularly as their accessibility expands.</p>\",\"PeriodicalId\":19448,\"journal\":{\"name\":\"Obesity Science & Practice\",\"volume\":\"10 4\",\"pages\":\"e783\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302371/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity Science & Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/osp4.783\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/osp4.783","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:最近批准的基于增量素的减肥疗法(如胰高血糖素样肽 1 激动剂 semaglutide)改变了肥胖症的治疗方法,但患者对这些药物的看法却知之甚少:2023年12月至2024年3月期间,来自美国东南部一家学术医疗中心、体重指数≥30 kg/m2的医护人员完成了一项横断面在线调查,内容是关于患者对增量肽类药物的态度:结果:与拥有学士学位的患者相比,没有学位的患者不太可能了解胰岛素类药物疗法(96% 对 78%),也不太可能与医生讨论过药物疗法(43% 对 27%),但他们对使用这些药物疗法有更大的兴趣(4.3 对 4.7)。这些与药物治疗相关的变量在性别、种族或经济保障方面没有明显差异。对副作用、长期健康风险和体重反弹可能性的担忧得到了高度认可,这些担忧与使用增量素疗法的兴趣较低以及一些人口统计学因素有关。患者对专为服用抗肥胖药物的人设计的生活方式计划很感兴趣:人口统计学因素,尤其是教育水平,应纳入促进公平使用胰岛素疗法的战略中,特别是随着胰岛素疗法可及性的扩大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Patient perspectives on incretin-based weight loss medications and relationship with demographic factors.

Objective: Treatment of obesity has been transformed by the recent approval of incretin-based therapies for weight loss (e.g., glucagon-like peptide 1 agonist semaglutide), but little is known about patient perspectives on these medications.

Methods: Between December 2023 and March 2024, healthcare patients from an academic medical center in the Southeast United States with Body Mass Index ≥30 kg/m2 completed a cross-sectional online survey on attitudes toward incretin-based medications.

Results: Compared to patients with a bachelor's degree, those without a degree were less likely to be aware of incretin-based pharmacotherapies (96% vs. 78%) and to have discussed pharmacotherapies with a doctor (43% vs. 27%) but had greater interest in using these pharmacotherapies (4.3 vs. 4.7). These pharmacotherapy-related variables did not differ significantly according to gender, race, or financial security. Concerns about side effects, long-term health risks, and potential for weight regain were highly endorsed and were associated with lower interest in using incretin-based therapies and with some demographic factors. Patients reported high interest in lifestyle programs designed for individuals taking anti-obesity medications.

Conclusion: Demographic considerations, notably education level, should be factored into the strategy to promote equitable utilization of incretin-based therapies, particularly as their accessibility expands.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Obesity Science & Practice
Obesity Science & Practice ENDOCRINOLOGY & METABOLISM-
CiteScore
4.20
自引率
4.50%
发文量
73
审稿时长
29 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信